Medtronic (NYSE: MDT) has received FDA clearance for its Stealth AXiS robotic system for spine surgery in the U.S. This system integrates planning, navigation, and robotics into a single platform and is designed for use in both hospitals and ambulatory surgery centers. A key innovation is the LiveAlign sentimental tracking feature, which allows surgeons to visualize real-time anatomic motion and patient alignment without repeated imaging, aiding in more consistent execution of surgical plans.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Medtronic wins FDA nod for surgical robot for spine procedures
Medtronic (NYSE: MDT) has received FDA clearance for its Stealth AXiS robotic system for spine surgery in the U.S. This system integrates planning, navigation, and robotics into a single platform and is designed for use in both hospitals and ambulatory surgery centers. A key innovation is the LiveAlign sentimental tracking feature, which allows surgeons to visualize real-time anatomic motion and patient alignment without repeated imaging, aiding in more consistent execution of surgical plans.